Ionis Pharmaceuticals Stock News

CARLSBAD, Calif. , March 21, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will present at the following investor conferences: Stifel 2022 Virtual CNS

– Treatment with donidalorsen in Phase 2 study significantly reduced angioedema attacks by 90% and provided improvement in quality of life – Published findings demonstrate favorable safety and tolerability profile of donidalorsen in Phase 2 study – Donidalorsen is one of Ionis'' wholly owned medicines the company plans to commercialize CARLSBAD, Calif. , March 16, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS ), the leader in RNA-targeted therapies, today announced the publication of positive Phase 2 data for donidalorsen (formerly IONIS-PKK-L Rx ) in the New England Journal of Medicine (NEJM) available at NEJM.org . Donidalorsen is an investigational antisense medicine Ionis is evaluating for treating patients with hereditary angioedema (HAE). In the Phase 2 study, donidalorsen demonstrated a 90% reduction in angioedema attacks compared with placebo at the 80 mg monthly dose. There was significant improvement in quality of life as assessed by the Angioedema Quality of Life Questionnaire (AE-QoL) in the patients treated with donidalorsen.

Astrazeneca PLC found using ticker (AZN) have now 5 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 70 and 59.5 calculating the average target price we see 66.98. Given that the stocks previous close was at 60.9 this now indicates there is a potential upside of 10.0%. The day 50 moving average is 58.73 and the 200 moving average now moves to 58.51. The market cap for the company is $188,315m. Find out more information at: https://www.astrazeneca.com [stock_market_widget type="chart" template="basic" color="green" assets=AZN" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $207,116m based on the market concensus. AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

Ionis has >$2 billion in cash, along with significant recurring revenue sources providing a solid foundation. It has had recurring difficulties in establishing increases to its product income.

Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news items possibly impacting those stocks

Upgrades Stifel upgraded the previous rating for Revolution Medicines Inc (NASDAQ:RVMD) from Hold to Buy. For the fourth quarter, Revolution Medicines had an EPS of $0.71, compared to year-ago quarter

CARLSBAD, Calif., March 1, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in a panel discussion on orphan neurological disease therap

Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to illustrate recent news items possibly impacting those stock

Teaser: Ionis (IONS) beats Q4 earnings and sales estimates. Stock rises.

Companies in The News Are: AEP,ATHM,IONS,DISH

Teaser: Ionis (IONS) beats Q4 earnings and sales estimates. Stock rises.

Ionis Pharmaceuticals, Inc. (IONS) CEO Brett Monia on Q4 2021 Results - Earnings Call Transcript

Ionis Pharmaceuticals press release (IONS): Q4 EPS of $1.41 may not be comparable to consensus of $0.31.Revenue of $440M (+51.7% Y/Y) beats by $155.92M.FY22 Guidance:Revenue to be…